Literature DB >> 9477109

The value of gallium imaging after therapy for Hodgkin's disease.

J A Bogart1, C T Chung, N F Mariados, A I Vermont, S M Lemke, S Grethlein, S L Graziano.   

Abstract

BACKGROUND: Although it is used widely, the value of gallium imaging in managing Hodgkin's disease remains unclear.
METHODS: A retrospective review of gallium imaging and treatment outcome in 60 patients with Hodgkin's disease treated between January 1990 and July 1995 was conducted. The minimum follow-up was 1 year.
RESULTS: Based on gallium imaging, 46 patients were in complete remission (CR) after initial treatment, 10 were in partial remission (PR), and 4 had persistent or progressive disease (NR). Ten of 29 patients (34%) with gallium CR after chemotherapy subsequently recurred, compared with no recurrences in 17 patients receiving initial radiotherapy or combined chemoradiation. Eight of ten patients received further therapy after gallium PR, and nine patients remained disease free at last follow-up. Survival did not differ in patients achieving a gallium CR or PR.
CONCLUSIONS: Gallium-67 imaging may help confirm the presence of active Hodgkin's disease, but was unreliable in defining disease remission after chemotherapy in this study population. Patients with a gallium PR may still have a good prognosis after additional therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9477109

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  Restaging with gallium scan identifies chemosensitive patients and predicts survival of poor-prognosis mediastinal Hodgkin's disease patients.

Authors:  I Ionescu; P Brice; D Simon; A Guermazi; T Leblanc; P Rousselot; D Gossot; V Meignin; C Gisselbrecht; J D Rain
Journal:  Med Oncol       Date:  2000-05       Impact factor: 3.064

2.  [The value of gallium scintigraphy after the therapy of Hodgkin's disease].

Authors:  S Staar
Journal:  Strahlenther Onkol       Date:  1998-12       Impact factor: 3.621

Review 3.  Gallium-67 scintigraphy: a cornerstone in functional imaging of lymphoma.

Authors:  Einat Even-Sapir; Ora Israel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-03-18       Impact factor: 9.236

Review 4.  The role of SPET and PET in monitoring tumour response to therapy.

Authors:  Chariklia Giannopoulou
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-06-14       Impact factor: 9.236

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.